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A retrospective study of high mobility group protein I(Y) as progression 
marker for prostate cancer determined by in situ hybridization
Y Tamimi1, HG van der Poel1, HFM Karthaus2, FMJ Debruyne1 and JA Schalken1
Summary In a previous study using RNA in situ hybridisation (RISH), we found a significant correlation 
between high mobility group protein I/Y, [HMG-I(Y)] mRNA expression and tumour stage and grade in 
prostate cancer patients, suggesting that HMG-I(Y) might be a potential prognostic marker in prostate cancer. 
However, our clinical lollow-up was limited because cryoprcscrved material was used. Assessing the potential 
prognostic value of this molccule is of importance because the clinical course of prostate cancer patients 
remains unpredictable. Here we describe our results on paraffin-embedded archival material from a group of 
102 patients undergoing radical prostatectomy. These were evaluated for the presence of HMG-I(Y) using 
RISH, and a follow-up of 12 -92 months (average 53 months) was available. In 2 of 14 prostate cancers in 
which the predominant histological pattern was of Gleason grade 1- 2, a high HMG-I(Y) expression was 
observed, whereas in 19 of 23 Gleason grade 3, and 34 of 35 Gleason grade 4 - 5  tumours, high HMG-I(Y) 
mRNA levels were detected (chi-square = 38.78, jPcO.OOOI). Moreover, of tumours that expressed high HMG- 
I(Y) levels, 25% were organ confined (T 1 — 2), in contrast to 74.5% of the invading tumours (T3, chi- 
square = 15.8, P < 0.001). Furthermore, 87% of recurrent tumours showed high HMG-l(Y) expression. 
However, a multivariate regression analysis including Gleason grade, clinical tumour stage, HMG-I(Y) 
expression and prostate-specific antigen (PSA) levels showed Gleason grade as the most accurate predictor of 
progression. High HMG~I(Y) levels measured by RISH were indicative of a worse prognosis, albeit that 
additional value over the more subjective grading methods was not evident.
Keywords: RNA in situ hybridisation; high mobility group protein; archival material; radical prostatectomy; 
multivariate analysis; prognostic marker
Prostate cancer is the most common malignancy among that is composed primarily of the iso form proteins H MG-1
males (Boring et al., 1994). Preventive screening programmes and HMG-Y (Johnson et al., 1988, 1989) and the closely
reveal more organ-confined lesions, leading to an increase in related I-IMGI-C (Manfioletti et al., 1991). Members o f  the
the number of radical prostatectomies. However, this may HMG-I(Y) family are distinguished from other groups of
not have a significant impact on overall survival as these HMG proteins by their ability to specifically bind to the
tumours show a variable clinical course that cannot be minor groove of A: T-rich DNA sequences (Elton et al.,
predicted with the current available markers. Thus, patients 1986; Solomon et al., 1986), presumably similar to anti-
with the same disease status may or may not progress tumour and antiviral drugs (netropsin, distamicin) and the
(Johansson et al., 1989; Adolfsson et al., 1990; Bostwick et Wegner
al., 1993) after radical prostatectomy. As cancer cells undergo In addition to its involvement in chromosome condensation
(Yang-yen et al., ; Giancotti et al., 1989), recent reports
role of HMG-I(Y) as a
atory factor (Fashena
aberrant patterns of differentiation, it is likely that their 
phenotype, including cellular components responsible for
differentiation, might be modified. Several biological markers transcription
have been studied in prostate cancer, but their prognostic Skalnik et
value is unknown. Some markers have been found to be p34alc2-like kinases phosphorylate the DNA-binding domains
associated with the onset of prostatic cancer, i.e. increased S- o f I-IMG-I(Y) both in vitro and in vivo (Meijer et al., 1991),
phase and elevated transforming growth factor (TGF)-/i1 
(Nagle et al., 1991). Other investigators have shown a
which may serve as an important regulatory mechanism for 
DNA-binding modulation (Disney et a l,
corrélation between the high expression o f  Ki-67, proliférât- corrélation between elevi
ing cell nuclear antigen (PCNA), MIB-1, and recurrent or neoplastic cell rmation (Giancotti
Johnson et al., 1988) and métastasés (Busscmakers et al., 
1991; Ram et al., 1993) has been found. In prostate cancer, 
we have shown significant correlation between I-IMG-I(Y) 
associated with progression in prostate cancer (Umbas et mRNA expression, Gleason grade and clinical stage
metastatic disease (Bostwick et al., 1992; Skalova et al., 
1994). We and others have shown that loss o f E-cadherin, a 
molecule involved in maintaining tissue integrity, is
al., 1992, 1994). Furthermore, decreased E-cadherin immu- 
noreactivity correlated not only with tumour grade and
(Tamimi et a l ,  1993). This finding prompted us to further 
analyse this molecule for its value as progression marker.
clinical stage but also with poor prognosis in patients with We report here on the retrospective study o f  HMG-I(Y) 
prostate cancer (Umbas et al., 1994), identifying E-cadherin mRNA expression in 102 radical prostatectomy specimens.
were
as a potential useful prognostic marker.
We have recently identified high mobility group protein 1/
Y [HMG-I(Y)], as a putative progression marker for 
prostate cancer (Bussemakers et al., 1991). I-IMG-I(Y) 
belongs to a family of chromosomal non-histone proteins the recurrence of the disease.
(Tamimi et al., 1993), image
to quantitate mRNA
As in our 
analysis
expression as detected by RISH. The results were compared 
with Gleason grade, clinical stage and, more importantly, to
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The Netherlands
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Materials and methods
Specimens from 102 consecutive radical prostatectomies 
performed in our institutions from 1985 to 1992 were
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included in this study. Samples were fixed in formalin and 
embedded in paraffin. A complete pathological examination 
was subsequently performed for each patient including pelvic 
lymph nodes. All the slides were reviewed by one of us 
(HGP) and, for each patient, a representative block was 
chosen for further analysis. In order to have accurate 
measurement of mRNA levels, paraffin-embedded tissue 
from the MAT-LyLu tumour, a metastatic subline of the 
Dunning rat prostatic cancer model system, was taken as an 
external reference. This allowed a good estimation o f the 
technique’s effectiveness. HMG-I(Y) is well conserved 
between species (85% homology between human and rat) 
and moderately expressed in MAT-LyLu.
Preparation o f  paraffin sections
Serial sections from each 
block corresponds to one 
thickness, mounted on 
adhesive glue solution and placed on a heating 
overnight at 50°C. The sections were depan
were
covered
block (each 
at 4 /an 
a 2% tissue
rehydrated in phosphate-buffered Si (PBS)
(1 x PBS= 137 mM sodium chloride, 2.7 mM potassium 
chloride, 8.1 mM disodium hydrogen phosphate, 1.5 mM 
potassium hydrogen phosphate pH 7), washed for 5 min in 
0.1 M glycine/PBS and incubated in 0.3% Triton X-100/PBS 
for 10 min. After a short rinse in PBS, sections were treated 
with proteinase K (10 pg ml-1) in 20 mM Tris-HCl, pH 7.5, 
5 mM EDTA for 15 min, post fixed in 4% paraformalde­
hyde/PBS for 5 min, rinsed in PBS and acetylated in freshly 
prepared 0.25% acetic anhydride/0.1 M triethanolamine, 
pH 8, for 10 min (Hayashi et al., 1978). The slides were 
then finally dehydrated in gradually increasing concentra­
tions of ethanol before hybridisation.
In situ hybridisation
Preparation of pSjUTP RNA probe, hybridisation, washing 
conditions and the preparation of microautographs were 
performed as described previously (Tamimi et al., 1993).
Stat is tic 'al anal vs is
w
For a comparison of the means corresponding to the four 
groups (Benign, Gleason grade: 1 -2 , 3 and 4 - 5 ) ,  the analysis 
of variance (/"-test) was performed on the A score (see 
previous paragraph). The recurrence rate of patients that have 
higher or lower HMG-I(Y) mRNA expression compared with 
a determined threshold was evaluated according to Kaplan -  
Meier (Kaplan et al., 1958), and the differences between 
groups were performed using the log-rank test.
Threshold determination
Although the choice of a cut-off value is arbitrary, it should 
not disequilibrate the groups in such a way that statistical 
methods are not applicable any more. The mean value ±(1  
or 2) x s.d. is the commonly used option in this particular 
case. We have chosen the mean value of Gleason grade 1 - 
plus 1.5 s.d. = 0.65 as a cut-off value for this study.
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Results
In order to evaluate the potential prognostic value of HMG- 
I(Y) expression in prostate cancer by RISH, we used archival 
specimens obtained after radical prostatectomy. Tissues were 
fixed in formalin, embedded in paraffin and stored until use.
Expression of  HMG-I( Y) determined by RISH
By rRNA hybridisation (rRNA + ), 75% of the samples 
showed appropriate RNA preservation and were investigated 
for the presence o f HMG-I(Y) mRNA by RISH. Table I 
summarises the HMG-I(Y) expression as the mean A 
values +  s.d. for the non-malignant tissue, and prostate tissue 
of Gleason grade 1—2, 3 and 4 - 5  respectively. In the non- 
malignant specimens the signals did not exceed background
(Figure 1, a -d ) .  We concluded that under these 
conditions HMG-I(Y) expression was below the detection 
limit of this technique.
?ason gi 1 - 0JL Jm fPreservation o f  RNA
In order to judge RNA preservation, samples were hybridised Fourteen cases of Gleason grade 1- 2 (well-differentiated
with sense and antisense 28S rRNA probes. The antisense tumours) (Gleason et al., 1977) showed clear expression of
rRNA probe signal had to exceed 10 x background to be HMG-I(Y), specifically on cancer cells within the glands. The
considered for inclusion in the study. Samples with poorly or mean expression level was 0.42 ±0.16. 
no preserved RNA (13%, 13 of 102) were rejected from the
analysis. Moreover, samples an experimental
failure in the external reference (9%, 9 of 102), or lacking 
follow up (3%, 3 of 102) were not studied.
Quantitation by image analysis
The consisted of a video camera (MXR, HCS,
Eindhoven) mounted on a routine light microscope, and a 
personal computer (Compaq Deskpro 386s, Compaq, 
Houston, TX, USA) equipped with a framegrabber board 
(VFG Visionplus-AT, Imaging Technology, Bedford, MA, 
USA). The output image was presented on a video monitor 
(PVM 1442QM, Sony, Tokyo). Software was written in TIM- 
image analysis language (TEA, Dordrecht). For each tumour 
area corresponding to highest Gleason grade, five images 
were randomly recorded at 40 x magnification. A Laplace 
filter was applied for grain identification. The mean number 
of grains per image was calculated for each slide and the 
following score for in situ HMG-I(Y) mRNA estimation 
could be derived:
Score A
i n R N A n M G - n Y j j , , , , )  -  i u R N A u m q - u y ) ; - )
m R N A r,,f. ( + ) -  m R N A „ , f. ( _ j
This calculates the expression of HMG-I(Y) ( + ) mRNA  
normalised for an external reference.
Gleason grade 3 tumours
Expression of HMG-I(Y) was detected in areas of the 23
tumours (Figure 
a lower signal similar to 
tumours. The mean HMG-I(Y) expression was 0.95 +  0.38.
Gleason grade 4 - 5
Thirty-live samples of poorly differentiated tumours showed a 
strong signal specific to tumour cells. A higher ‘grain density’ 
was obtained in this category of tumours when compared
Table I HMG-I(Y) expression in prostate cancer determined by 
RISH on paraffin-embedded tissue from patients who underwent
n prostatectomy
Differentiation
Benign
Gg (1-2) 
Gg (3)
Gg (4 “ 5)
Number o f cases
■ ■ tm »K W H * I 1 ^  A* g* h
6
14
23
35
Mean o f  score 
A ±s.d.
0.03 ±0.04 
0.42 ±0.16 
0.95 ±0.38 
1.34±0.52
HMG-I(Y) mRNA levels expressed as normalised A score (see 
Materials and methods) in non-malignant (B), Gleason grade (Gg) 1 -  
2, Gleason grade 3, and Gleason grade (4-5) tumours.
•uotssaidxs (a )I-O J\H  si^ bas oí ([ ‘q ‘p) (a )I-OWH
o su o s  o q i  put? l(5j ‘8  ‘o) ( a ) I - O W H  asuospuB qjjM psuuojjsd si; ay uoi)3stpuq/(i[ a q x  ‘(uoijBAJasajd V N 'H  s s s s sb  o j )  (f ‘j  ‘q) V N ^I-1 
3SU3S ‘(! ‘9 **) V N > J J 3SU0SI1UB qiiM  pasipuq^ti s-iom suo ¡pas pappoqura-uiyiutjj -(j ‘>| ‘f ‘¡) ç - f r  pm? (q ‘8 ‘j  ‘a) £ op&iS uosbsio J° 
sunuuoods jum iSpm  (p ‘a ‘q ‘b) anssp juBuSpui-uou v, u o  (q^ x  ) uoipoyuithuu pjuiSuo hSR I J °  ssidutBXS 3A|jBiu9SSid8>| \
rÄlii®:Ppliliiäp m t t n i i
: . è f
+mmmm
iikâmÿk
'(Sc0‘0 = J  'g¿l(rs = 3.renbs-íip :isoj ^mu-Soj 
£ o-inSy) uoisso.i3o.Td pire uoissojdxo (A)l"OíMH uaoMioq 
uoireiauoa îiniomuSis t? domoits sisXnure .taraïAi -uindB'sr
■(l£ J° VI i%Ç'LL) îjswosip 
XîuofBui oqi i[]iav ‘(S9'0<V)£ d3«-)s pîDiutp ojui 
suouuoads .molimi .noip ui uoissojdxo (A)I’OIMH
poMoqs (je jo Hc ‘%06) ^traimi JO lSOJ/\¡
DM)) pu Su ç'O^VSd *3' !  ^ipîoiuioipoiq j o  /Cipioiuijo
uoisscuSojd jo OOUOPJAO po/woqs (ZL j:o i£) iiioo .t o d ncuqi
■sijiuoiu 96 oi uiojj poSirej siuoin?d jo dn moho£j
s jsX fm tn  i w m v . t â o . t j
/Çpnis siip ni on [tu jtmopippi?
p3.msB3iu sum y s d  '(a )I'OIAIH J° sj3A3¡ uoissojdxo aqj qiiAV 
VSd J° spA3| jusntïd parediuoo oav ‘aptuS uostojo J° 
S0S15O osoip ui Amojooiniso-id jTOiptw .layt! sitqsojd oqi opisino 
piîsjds Xpiísaj-R pt?q asiissip aqi .laqiaqAV ssassu oi .lapjo iq
u o t i D j a j u o .} u o is s 'd.u Ix d  ( a ) I ~ D M H  P l w  s'lMr’)] V S d
•(III W * 1  938
"100*0 = </ ‘8-çi=arenbs-iqo) pire e i  «ï % 16 ™ z j l + u  
ut o/oÇZ '3-i ‘gsTîssip sStfjs-qSiq qjiM pa^toossi? stîm (ç9'0<V )
uoissojdxa (à )I"OIAIH R^ÏH 'sStîjs p?3iuip qjiM psi^puoD 
(Ç9'0 jo  pjoqsaup poxg. sqj laAo) uoisssjdxs (a )I-OHH  
.T3ipai[M pajtmpua OM ‘sjnoumi jo ssousaisbaui put! ssauaAis
ou SBij Äiuopoii?iso.id p?3iptîj jojj« pojnsraiu sti |oaoj y g j  -so.iSSt? qiiM. poiBioossi? oq iqSiiu (A)l'OIAIH J° uoisso.idxo 
jrnp paiB.tisuotuop sisÁpmt? uoisso.i§3.r .raqijnj y  '(£9‘0 < V ) pos^aioin jiup Sui.ropisuo^ (z  o.inSij sas) opR.i§ uost?o[q
uoissojdxa (ä )I_OIAIH lI^ !M ps^oqs OAU Xyuo qilM P3S1Î3.I0UI U0TSS9.ldX3 (A)I"0P\1H pSl^OIpUl SISÄJBUR
‘j9A3A\oq (z apiu§ uosbsjo siuoriBd .moj ‘c opmS uosuojq oqx '(H ui sonji’A-j- pun } aas) punoj o.iom sdnojg ni?
siuoq^d j n o i 1
(Lief luopnd ano sjuopiïd noi) oSuis-qSiq o.u ï  siuoiiud Á¡n?oiisin?ig
VSd I3A0j-q8iq osoqi jo  isojaI •sjuoiiiïd \ \ Ä[uo ut t im Su ç o
DAoqiï asp S|3A3| ysd  ‘posXpun? siuojittd ZQ\ Suouiy 'siuonud sjnoumi £
USOMPq S[3A3{ U0TSS3jdX3 (A)I"0IAIH Ui S30U3.T3J.Jlp lUTÎ3lJTllSlS
.mo s3su\5iiiiuns ¡i oiqi^x
uoswajn put? z  -  I
•(I- i  ‘t 3.inSy)
UO St?3T0 qi|AV
;e id itujLuej. a
J80UB0 STBTSOjd J8^JBUJ se (a)I~OIAIH
575
HMG-i(Y) as marker for prostate cancer
Y Tamimi et al
Discussion
Increased HMG-I(Y) mRNA are often found in
rapidly proliferating or undifferentiated cells and in various 
malignant tissues including prostate cancer (Lund et a/., 1983; 
Elton et al., 1986; Johnson et ill., 1988; Bussenmkers et al., 
1991). Furthermore, induction o f differentiation results in the 
down-regulation of HMG-I(Y) mRNA expression, suggesting
of the higher numbers of biologically aggressive 
cells in the latter tumours. Furthermore, 28 of 31 patients 
(90%) that showed recurrence of disease showed high HMG- 
I(Y) expression (A >0.65). This is in agreement with previous 
studies on mouse teratocarcinoma cells (Vartianen et al 
1988) and mouse neoplastic cells induced by different 
procedures (Giancotti et a l ., 1989). In the present study we 
show that patients with low HMG-I(Y) expression are at low
that HMG-I(Y) expression is associated with cellular risk of recurrence as only 3 of 17 (17.6%) relapsed. In
differentiation (Vartianen et al ., 1988). In a previous study 
we showed that in specimens o f non-malignant prostate 
tissue, HMG-I(Y) expression was absent, whereas HMG-I(Y) 
expression was clearly detectable in prostate cancer cells 
(Tamimi et al., 1993). Moreover, a statistically significant 
correlation between the level o f  HMG-I(Y) expression and 
Gleason grade and stage was found (Tamimi et al., 1993). 
The present data on archival specimens confirm our previous 
findings (Figure 2) and corroborate the hypothesis that 
HMG-I(Y) expression is related to differentiation. Indeed, in 
well-differentiated tumours 2 of 14 cases (14%) showed low 
HMG-I(Y) expression, whereas 83% (19 of 23) of moderately 
differentiated and 97% (34 o f 35) o f poorly differentiated
tumours showed high (chi-HMG-I(Y) expression 
square =  38.78, P<0.0001). This strong correlation between 
tumour grade and HMG-I(Y) expression, determined by 
RISH, suggests that this might be used as an additional 
prognostic indicator for prostate cancer. However, a multi­
variate regression analysis, which included Gleason grade, 
tumour stage, HMG-I(Y) expression and PSA levels showed 
Gleason grade as the most accurate predictor o f progression 
(chi-square =  21.35, P<0.0001). In this study, high HMG- 
I(Y) levels as measured by RISH were indicative o f a worse 
prognosis, although additional value over the more subjective 
grading methods was not evident.
We found that HMG-I(Y), as measured with image 
analysis, was highly expressed in 14 of 27 cases o f tumours 
(51%) that were organ confined ( T l - 2 )  in contrast to 41 of  
45 tumour cases (91%) invading through the prostate capsule 
(T 3-4 ). Thus, there seems to be a trend towards higher 
HMG-I(Y) levels in higher stage tumours, which might be a
Table II Statistical analysis of data obtained on paraffin tissue from
a patient who underwent radical prostatectomy
Group Mean values o f  A :t“ S.d. t- value P-value
Gg 1 -2 0.42 it 0.16 4.79 (<  0.0001)
Gg 3 0.95 ± 0,38
Gg 1-2 0.42 rh 0.1 6 6.03 (<  0.0001)
Gg 4 - 5 1.34 àz 0,52
Gg 3 0.95 ± 0.38 3.07 ( = 0.0030)
Gg 4 -  5 1.34 rb 0.52
/-test was performed to compare (two by two) the groups for their 
HMG-I(Y) expression. Gg, Gleason grade.
contrast, patients with high HMG-I(Y) expression had a high 
frequency of recurrence in 28 o f 55 cases (51%). However, 
HMG-I(Y) expression was not indicative of progression in all 
cases: in three patients with low HMG-I(Y) expression 
(A <0.65), and low-stage disease (T1 one case, T2 two 
cases) relapses were observed. The reverse was also observed 
in two patients: low HMG-I(Y) was measured despite high 
Gleason grade and stage. Nevertheless, HMG-I(Y) expression 
might be predictive for the malignant potential of prostate 
cancer cells.
The mechanism by which the HMG-I(Y) gene is regulated 
in prostate tissue remains to be elucidated. The proteins are 
present in abundance (10s— 10° molecules per cell), which 
indicates that they could be involved in the regulation of 
many genes, some o f  which might be involved in cell growth. 
Recently, Friedmann et al. (1993) localised the HMG-I(Y) 
gene to the short arm of chromosome 6 in a region where 
rearrangements, translocations and other abnormalities have 
been found in numbers o f human cancers.
HMG-I(Y) has been implicated in a number o f  functions: 
the subunits o f  NF-kB (p50 and p65), members of the 
oncogene rel family, can only activate transcription from 
their binding site PRDII when HMG-I(Y) is also bound 
(Thanos et a l 1992), similarly the E-selectin gene, encoding 
for endothelial cell adhesion proteins, can be activated only 
via interleukin (IL)-13 and tumour necrosis factor (TNF)-a 
induction o f  NF-tcB through HMG-I(Y) binding (Lewis et 
al . ,  1994). HMG-I(Y) is involved in rescuing scaffold- 
associated regions (SARs) and A:T rich sequences from 
histone HI-mediated repression, which fold the chromatin
into higher order structures (Zhao et al., 1993); finally
in the suppression of IL-4 
transcription in T lymphocytes (Chuvpilo et al., 1993), as 
well as in the stimulation of a specific isoform of the 
activating transcription factor 2 (ATF-2|95) binding to
HMG-I(Y) plays a r
interferon fl (IFN-/Ï) (Du et al., 1994). In view of the 
multifunctionality o f  HMG-I(Y) in mammalian cells, it is not
Table III Relation between HMG-I(Y) expression levels and stages
m o n
77 712 73 T4
A < 0.65 
A >  0.65
0
I
13
13
4
40
0
I
Correlation between stage and HMG-I(Y) expression over and 
below a threshold of 0.65 (normalised score A).
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Figure 2 Correlation of HMG-I(Y) expression with Gleason 
grade (Gg) in prostate cancer.
Figure 3 Kaplan 
I(Y) expression.
(------) HMG-I(Y)
Meier progression free rate related to HMG- 
Log-rank test: chi-square = 5.017, P =  0.025. 
0.65; (------- ), HMG-I(Y)>0.65.
surprising that high HMG-I(Y) expression is important in 
cancer progression. The results presented here indicate that 
measurement of HMG-I(Y) levels in prostate cancer may be
as a prognostic marker. However, the technical 
difficulties of RISH should be taken into account for routine 
use. The development of less cumbersome techniques for 
HMG-I(Y) detection, i.e. immunohistology, is necessary 
before this can be implemented.
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